Teva Phase IV UNITE Study Shows AJOVY (fremanezumab) Reduced

Teva Phase IV UNITE Study Shows AJOVY (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

17.10.2023 - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce that data from the UNITE study presented today at the World Congress of Neurology in Montreal, Canada, show that AJOVY (fremanezumab) reduced migraine attacks and depression symptoms ... Seite 1

Related Keywords

Verena Ramirez Campos , Patient Health , Global Senior Medical Director , Monthly Migraine Days , Hamilton Rating Scale , Teva Pharmaceutical Industries Chart , Eva Pharmaceutical Industries Kurs , Teva Pharmaceutical Industries Aktie ,